<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03671421</url>
  </required_header>
  <id_info>
    <org_study_id>B2016:066</org_study_id>
    <nct_id>NCT03671421</nct_id>
  </id_info>
  <brief_title>Number One Overall Graft Pick? Hamstring vs Bone-Patellar-Tendon-Bone vs Quadriceps Tendon</brief_title>
  <official_title>Number One Overall Graft Pick? Hamstring vs Bone-Patellar-Tendon-Bone vs Quadriceps Tendon: A Prospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Panam Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Panam Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to determine if there is a difference in graft&#xD;
      re-injury/failure rates between participants that have had an ACL reconstruction with a STG,&#xD;
      BPTB or QT autograft. Additionally, to compare quality of life, patient reported outcomes and&#xD;
      functional performance after ACL reconstruction with STG, BPTB and QT.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main purpose of this study is to determine if there is a difference in graft&#xD;
      re-injury/failure rates between participants that have had an ACL reconstruction with a STG,&#xD;
      BPTB or QT autograft. Additionally, to compare quality of life, patient reported outcomes and&#xD;
      functional performance after ACL reconstruction with STG, BPTB and QT.&#xD;
&#xD;
      Quasi-randomized clinical trial&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 11, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective quasi-randomized clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The clinical assessments will be done by someone blinded to the arm of the study the patient is in.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>graft re-injury (re-rupture, partial tear) or graft failure</measure>
    <time_frame>24 months</time_frame>
    <description>) Diagnosis of a complete graft re-rupture requires all of the following criteria to be met:&#xD;
associated with an acute traumatic event&#xD;
a definite loss of end point on manual Lachman testing&#xD;
increased anterior translation &gt;3 mm&#xD;
&gt; or = Grade 2 pivot shift&#xD;
tear confirmed as complete on MRI or diagnostic arthroscopy&#xD;
revision ACL reconstruction IS recommended or required&#xD;
2) Diagnosis of a partial re-rupture requires all of the following criteria:&#xD;
suspected meniscal injury or graft tear on history without the clinical characteristics of a complete rupture&#xD;
tear confirmed as partial by MRI or diagnostic arthroscopy&#xD;
revision ACL reconstruction is NOT recommended or required&#xD;
3) Diagnosis of graft failure will be defined as:&#xD;
&gt;/= Gr. 2 pivot shift and/or &gt;6 mm side-to-side difference on manual Lachman</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SANE</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knee laxity</measure>
    <time_frame>24 months</time_frame>
    <description>KT1000 Knee Laxity Arthrometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentric maximal strength</measure>
    <time_frame>24 months</time_frame>
    <description>Knee flexion and extension strength - biodex</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain log</measure>
    <time_frame>3 weeks post operative</time_frame>
    <description>type and quantity of pain medication use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACL-QOL</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-12</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">286</enrollment>
  <condition>Anterior Cruciate Ligament Rupture</condition>
  <arm_group>
    <arm_group_label>Quads tendon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The graft tissue will be quadriceps tendon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hamstring</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Semitendinosus and gracilis will be used for graft</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BPTB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bone patellar tendon bone graft to be used.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ACL reconstruction - graft choice</intervention_name>
    <description>Use of 3 different ipsilateral autograft options</description>
    <arm_group_label>BPTB</arm_group_label>
    <arm_group_label>Hamstring</arm_group_label>
    <arm_group_label>Quads tendon</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  - confirmed diagnosis of a complete primary unilateral ACL rupture based on all of the&#xD;
             following:&#xD;
&#xD;
          -  history of a traumatic injury episode&#xD;
&#xD;
          -  physical exam findings of increased anterior translation of the tibia on the femur&#xD;
             (Lachman test and/or anterior drawer test)&#xD;
&#xD;
          -  positive pivot shift test&#xD;
&#xD;
          -  patients must be 14 to &lt;/= 50 years (at time of surgery)&#xD;
&#xD;
          -  x-rays showing skeletal maturity (i.e. tibial tubercle fused) and no fractures&#xD;
&#xD;
          -  MRI prior to surgery (note: if the radiologist's report states an incomplete or&#xD;
             partial ACL on MRI but the surgeon diagnoses the patient with a complete unilateral&#xD;
             tear based on the clinical criteria above, then the patient will be considered&#xD;
             eligible. Final eligibility will be determined intra-operatively.)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  - ACL rupture on contra-lateral limb&#xD;
&#xD;
          -  Partially torn ACL *final determination made intra-operatively&#xD;
&#xD;
          -  Concomitant medial collateral, lateral collateral, or posterior collateral ligament&#xD;
             tears requiring surgical repair *final determination made intra-operatively&#xD;
&#xD;
          -  Severe chondromalacia (Grade IV on the ICRS scale) *final determination made&#xD;
             intra-operatively&#xD;
&#xD;
          -  ACL reconstruction using allograft tissue&#xD;
&#xD;
          -  Confirmed connective tissue disorder&#xD;
&#xD;
          -  Unwillingness to be followed for 24 months post-operatively&#xD;
&#xD;
          -  History of rheumatoid arthritis&#xD;
&#xD;
          -  Pregnancy (at the time of surgery)&#xD;
&#xD;
          -  Psychiatric illness that precludes informed consent&#xD;
&#xD;
          -  Unable to speak, read or understand the English language&#xD;
&#xD;
          -  Major medical illness (life expectancy less than 1 year or unacceptably high operative&#xD;
             risk)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pan Am Clinic</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3M3E4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheila McRae, MSc, PhD</last_name>
      <phone>204.925.7469</phone>
      <email>smcrae@panamclinic.com</email>
    </contact>
    <contact_backup>
      <last_name>Dean Cordingley, MSc</last_name>
      <phone>204.925.5858</phone>
      <email>dcordingley@panamclinic.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sheila McRae, MSc, PhD(C)</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Greg Stranges, MD, FRCSC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter MacDonald, MD, FRCSC</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jarret Woodmass, MD, FRCSC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 11, 2018</study_first_submitted>
  <study_first_submitted_qc>September 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2018</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Panam Clinic</investigator_affiliation>
    <investigator_full_name>Peter MacDonald</investigator_full_name>
    <investigator_title>Department head, orthopaedic surgery</investigator_title>
  </responsible_party>
  <keyword>Graft choice</keyword>
  <keyword>hamstring</keyword>
  <keyword>quadriceps tendon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rupture</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

